{
  "docId": "019de070-cb6f-702e-8ba7-38c2ee57750d",
  "docSlug": "70846fe5de6d20355c3868d80f4845b0",
  "documentTitle": "BioNTech | Results Presentation Deck | 36 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 36,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a process flow diagram to illustrate the trial structure from patient selection to expansion cohorts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-cb6f-702e-8ba7-38c2ee57750d/23",
  "deckHref": "/decks/019de070-cb6f-702e-8ba7-38c2ee57750d",
  "deckJsonHref": "/decks/019de070-cb6f-702e-8ba7-38c2ee57750d.json",
  "deckAnchorHref": "/decks/019de070-cb6f-702e-8ba7-38c2ee57750d#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.92,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Trial flow from patient selection to Part 1/2 dose escalation and Part 3 expansion cohorts.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f783de15-944b-41fd-9281-8467b3fa2590",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.65
      },
      "kind": "paragraph",
      "text": "Phase 1/2a: Evaluation of safety and tolerability of CLDN6 CAR-T +/- CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors. 3+3 dose escalation with bifurcated trial design",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e97a0261-8168-40be-b56c-bf7ec148da6e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.08,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "NSCLC, Non-Small Cell Lung Cancer; CLDN6, Claudin-6; CAR-T cells, Chimeric Antigen Receptor engineered T cells; RNA-LPX, RNA-lipoplex; MTD, maximum tolerated dose; RP2D, recommended Phase 2 dose; NOS, not otherwise specified (e.g. rare tumors)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f08d956c-e6d9-48f3-aad9-9b518d6aaca0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "BNT211: First-in-human CARVac trial with first data expected this year",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15ddde28-7bfe-4bd9-a05a-874c2e9105f4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "468a40e4-d876-4526-a07c-35bafa530717",
      "evidence": "The slide uses a flow diagram to show the progression of a clinical trial.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}